Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) has provided an announcement.
Oncopeptides AB announced it will release its second-quarter 2025 financial report on August 21, 2025, followed by a webcast and Q&A session for investors, analysts, and media. This event will be led by CEO Sofia Heigis and CFO Henrik Bergentoft, providing insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company utilizes its proprietary Peptide Drug Conjugate platform to create compounds that selectively deliver cytotoxic agents into cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnerships in South Korea, the Middle East, and Africa. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 4,742,784
Technical Sentiment Signal: Buy
Current Market Cap: SEK950.7M
See more data about ONCO stock on TipRanks’ Stock Analysis page.